The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AERPIO PHARMACEUTICALS INC | COM | 00810B105 | 516 | 400,000 | SH | DFND | 1 | 400,000 | 0 | 0 | |
| ATEA PHARMACEUTICALS INC | COM | 04653R106 | 162,969 | 2,639,178 | SH | DFND | 1 | 2,639,178 | 0 | 0 | |
| IDERA PHARMACEUTICALS INC | COM PAR | 45168K405 | 73 | 56,250 | SH | DFND | 1 | 56,250 | 0 | 0 | |
| GENOCEA BIOSCIENCES INC | COM NEW | 372427401 | 1,016 | 375,000 | SH | DFND | 1 | 375,000 | 0 | 0 | |
| NABRIVA THERAPEUTICS PLC | SHS | G63637113 | 76 | 45,849 | SH | DFND | 1 | 45,849 | 0 | 0 | |
| PULMONX CORP | COM | 745848101 | 38,117 | 833,333 | SH | DFND | 1 | 833,333 | 0 | 0 | |
| SYNLOGIC INC | COM | 87166L100 | 737 | 205,906 | SH | DFND | 1 | 205,906 | 0 | 0 | |